AOAC RESEARCH INSTITUTE
Expert Review Panel Chair Report for Veterinary Drug Residues – Dyes in Seafood
Page 5 of 6
MEETING MINUTES
I.
Welcome and Introductions
The Expert Review Panel Chair, Dr. Joe Boison of the Canadian Food Inspection Agency (CFIA) members, and
discussed the goal of the meeting.
II.
Review of AOAC Volunteer Policies & Expert Review Panel Process Overview and Guidelines
Deborah McKenzie presented a brief overview of AOAC Volunteer Policies, Volunteer Acceptance
Agreement and Expert Review Panel Policies and Procedures which included Volunteer Conflicts of Interest,
Policy on the Use of the Association, Name, Initials, Identifying Insignia, Letterhead, and Business Cards,
Antitrust Policy Statement and Guidelines, and the Volunteer Acceptance Form (VAF). All members of the
ERP were required to submit and sign the Volunteer Acceptance Form. In addition, she also presented an
overview of the ERP process including meeting logistics, consensus, First Action to Final Action
requirements, and documentation.
III.
Discuss Final Action Requirements for First Action Official Methods
All ERP members presented a review and discussed the information received from the method author for the
AOAC First Action method AOAC 2012.25: Three Triphenylmethane Dyes Residues and Their Metabolites
(Malachite Green, Leuco Malachite Green, Crystal Violet, Leuco Crystal Violet, Brilliant Green) In Aquaculture
Product, LC‐MS/MS, First Action 2012
,
which has approached the 2‐year tracking period.
The method
authors, Wendy Andersen of United States Food and Drug Administration, and Eric Verdon of ANSES ‐
French Agency for Food, Environmental and Occupational Health & Safety, were present and able to address
the questions and concerns of the ERP. A summary of comments was provided to the ERP and the method
authors.
2
The ERP is required to make a recommendation on AOAC Official First Action methods, 2 years
after adoption, to the AOAC Official Methods Board regarding Final Action status. By consensus the ERP
presented the following motions for AOAC 2012.25
:
Motion by An; Second by Martos,
to recommend to the AOAC Official Methods Board, First Action
Method AOAC 2012.25 for AOAC Final Action Official Methods status.
Consensus demonstrated by: 7 in favor, 0 opposed, and 0 abstentions. Unanimous,
Motion Passed.
The ERP members noted additional discussion items regarding the details of the recommendation for AOAC
Final Action Official Methods status that will assist in the AOAC Official Methods Board review.
Strengths, Weakness, and Community Needs
The method is easy to follow, speedy, flexible, has a broad scope, and can be evaluated amongst
different matrices that will benefit the community that it serves. In addition, there are many
publications available that help support the method. It was also noted that the method will be
moving forward as an FDA Regulatory standard due to the data being easily reliable.
Reference Materials
The ERP noted that there are currently no reference materials available for these types of drugs and
may need someone to generate reference materials in the future. The compounds are declared not
acceptable for daily intake and cannot be used in fish production. The ERP should continue to
monitor for future implementation in regulatory environments.
2
Attachment 1: Summary of Expert Reviewer Comments for AOAC 2012.25
ERP PROFILE SUMMARIES
112